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IT is widely recognized that PSA has low positive predictive value for clinically significant prostate cancer. A number of markers are now available to aid with prostate cancer decision making in men with moderately elevated PSA. 1 The 4 kallikrein panel, which is commercially available as the 4Kscore, is a statistical model incorporating patient age, total PSA, free PSA, intact PSA, hK2, DRE and prior biopsy. The panel has been shown to accurately predict the risk of Gleason Grade Group 2 or greater (high grade) cancer on prostate biopsy and the long-term risk of prostate cancer metastasis. 2 Intact PSA and hK2 are 2 markers that distinguish the kallikrein panel from other models. Therefore, it is obvious to ask whether these 2 additional markers add discrimination to the clinical predictors of age, DRE and prior biopsy, and to the established molecular markers total and free PSA. This question has been directly addressed in some studies. For instance, in the prospective 4Kscore American validation study of 1,012 men who underwent biopsy at 1 of 26 urology clinics the AUC of 0.821 was reduced to 0.751 when intact PSA and hK2 were excluded from the model. 3 However, an analysis of the marginal benefit of the novel markers has not been reported in all cohorts and results have not been combined across studies.
We performed an individual patient data metaanalysis to assess the improvement in discrimination by adding intact PSA and hK2 to a prespecified model including age, total PSA and free PSA.
MATERIALS AND METHODS
Data were received on previous biopsy cohorts as in a prior individual patient data meta-analysis. 4 The cohorts were in the ProtecT, Rotterdam ERSPC, Rotterdam Repeat Biopsy, UPCA, Tarn ERSPC, G€ oteborg ERSPC and OPKO Health studies. 4 One additional study in a VA (Veterans Affairs) cohort, published after the prior metaanalysis, was also included. 5 The IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) study was not included as there were only 7 high grade cancers in this cohort. 6 The authors of 1 study did not give us permission to use their data in this metaanalysis. 7 Three previously published models were used to generate predictions of the risk of high grade disease (Gleason Grade Group 2 or greater, Gleason score 7 or greater) based on the kallikrein panel. The first model, which was the G€ oteborg model, 8 was replaced by the Rotterdam model 9 when changes were made to the kallikrein assays. To reflect changes in biopsy practice (extended biopsy schemes) and grading (redefinition of some Gleason 3 pattern cancers as pattern 4) the ProtecT model was developed for contemporary cohorts. 10 Models were applied to each cohort according to the original publication so that the G€ oteborg model 8 was applied to the G€ oteborg ERSPC cohorts, 4 the Rotterdam model 9 was applied to the Rotterdam and Tarn ERSPC cohorts, 4 and the ProtecT model 10 was applied to the contemporary ProtecT, UPCA, OPKO Health 4 and VA 5 cohorts. The AUC of the 4 kallikrein model was compared to a model of age, total PSA and free PSA but setting the value of all hK2 and intact PSA levels to zero. As a sensitivity analysis the AUC of the kallikrein models was compared to the performance of comparator models built on the same cohorts but which excluded intact PSA and/or hK2. All models also included the DRE result if this information was available.
Predictions from the 4Kscore are based only on total PSA when PSA is 25 ng/ml or greater. Therefore, patients with PSA higher than 25 ng/ml were excluded from all analyses. Except for the Rotterdam Repeat Biopsy cohort, in which all patients had a prior negative biopsy, 4 patients with a history of prior negative biopsy were excluded.
To obtain the SE of the AUC improvement when including the additional markers, the method of DeLong et al was used. 11 In the G€ oteborg round 1, Rotterdam round 1 and ProtecT cohorts in which models where built and assessed in the same cohort, 4 the method of Delong et al 11 was invalid to determine the difference in nested models. Thus, we used bootstrap resampling to estimate the SE around the difference in the AUC. We then metaanalyzed the difference in the AUC and the SE of this difference to test whether adding intact PSA and hK2 significantly improved discrimination. As a sensitivity analysis we repeated these analyses including only the 4 contemporary biopsy cohorts, that is OPKO Health, ProtecT, UPCA 4 and VA. 5 All analyses were performed with StataÒ, version 13.
RESULTS
A total of 14,510 men from 10 cohorts were included in this individual patient data meta-analysis. Table 1 lists patient and disease characteristics. Table 2 and the figure 4 show the results of individual studies and meta-analytical estimates. Note that the reported results may not match those in the original publications 4 due to the exclusion of some patients with prior negative biopsy and those with total PSA greater than 25 ng/ml. The fixed effects, meta-analytical estimate of the AUC in the model without intact PSA and hk2 was 0.742 (95% CI 0.727e0.756) compared to 0.813 (95% CI 0.801e0.825) for the full kallikrein model. The 95% CIs did not overlap and the difference in discrimination was highly statistically significant (0.069, 95% CI 0.057e0.080, p <0.0001).
We also wanted to investigate the marginal improvement in AUC when adding intact PSA and hK2 separately. When adding intact PSA to the model including age, total PSA, free PSA and DRE, the AUC ranged from 0.708 to 0.885. The AUC increased significantly by 0.059 (95% CI 0.050e0.069, p <0.0001) to 0.802 (95% CI 0.789e0.814, p <0.0001). The marginal improvement in discrimination when adding hK2 to the model including age, total PSA, free PSA and intact PSA was smaller but significant at 0.024 (95% CI 0.020e0.029, p <0.0001), indicating that intact PSA and hK2 significantly increased discrimination when alone as well as when combined.
There was significant heterogeneity between the cohorts for model discrimination (p 0.01). This was expected as the patient groups and indications for biopsy differed between the cohorts. For instance, discrimination was higher in the 2 models in cohorts undergoing a first PSA than those undergoing repeat screening. However, critically there was no heterogeneity in the AUC improvement for intact PSA and hK2 (p ¼ 0.2).
When limiting analysis to the 4 contemporary cohorts, 4,5 discrimination was slightly lower in all models. However, increases with the addition of intact PSA and hK2 remained significant and were consistent with those seen in the main analysis. Among these cohorts discrimination in the model without intact PSA and hK2 was 0.723 (95% CI 0.706e0.740). Discrimination when adding intact PSA and hK2 was 0.794 (95% CI 0.779e0.809), representing an increase of 0.071 (95% CI 0.057e0.085, p <0.0001). Adding intact PSA alone increased discrimination by 0.063 (95% CI 0.052e0.074, p <0.0001) to 0.786 (95% CI 0.771e0.801). Further, hK2 alone improved discrimination by 0.026 (95% CI 0.021e0.032, p <0.0001) to 0.753 (95% CI 0.737e0.770).
As a sensitivity analysis requested by a reviewer, we repeated the analysis comparing the kallikrein models to the performance of comparator models built on the same cohorts which excluded intact PSA and hK2. The results were similar. The AUC of the model without intact PSA and hK2 was 0.784 (95% CI 0.771e0.797) compared to 0.813 (95% CI 0.801e0.825) for the full kallikrein model. The 95% CIs did not overlap and the difference in discrimination was highly statistically significant at 0.027 (95% CI 0.021e0.034, p <0.0001).
DISCUSSION
Our findings clearly demonstrate that intact PSA and hK2 add importantly to the discrimination of the kallikrein panel. Although the marginal value of intact PSA and hK2 has been reported in some studies, such as the American validation study, 3 to our knowledge the current meta-analysis is the first attempt to systematically estimate the value of these 2 markers across different studies. To date it had been possible that the high discriminatory accuracy of the kallikrein panel reported across numerous studies was due to the free and total PSA components. If so, the clinical value of the panel, which was to reduce unnecessary biopsy and over diagnosis, could be replicated using data readily available to urologists without measuring additional markers. We have disconfirmed this hypothesis.
The value of hK2 might still be questioned on the ground that a greater part of the value of the novel markers comes from intact PSA. However, a 0.024 increment in AUC for hK2 is far from trivial. Moreover, hK2 has clear value in the context of multiplex testing. Given that blood needs to be sent to a special laboratory for testing intact PSA, and total and free PSA values are tested simultaneously, including hK2 has no effect on timeliness or inconvenience and only a marginal increase in cost.
CONCLUSIONS
In an individual patient data meta-analysis of intact PSA and hK2 statistically significant predictive discrimination was added to the kallikrein panel with nonoverlapping CIs for the estimates of discrimination of the panel with and without these 2 markers. The increment in discrimination had clear clinical benefit. The clinical value of the panel could not be replicated using data readily available to urologists without measuring intact PSA and hK2.
